top stories

Sanofi and Am­gen are bring­ing cash to cov­er the ta­ble stakes for the Hori­zon M&A game

3 hours ago
Deals

Pfiz­er backs $60M in­fu­sion in­to Car­rick, teams up on breast can­cer treat­ment

1 hour ago
Financing
R&D

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls

Yesterday
R&D
In Focus

Latest

Most read

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

17 hours ago
FDA+

FDA re­jects Y-mAbs’ neu­rob­las­toma drug af­ter tak­ing is­sue with clin­i­cal tri­al de­sign

1 hour ago
R&D
FDA+

Philip Tagari switch­es Am­gen's dis­cov­ery lab for in­sitro's ma­chine learn­ing tools; CEO Joaquin Du­a­to to chair J&J's ...

1 hour ago
Peer Review

Rigel Phar­ma scores FDA ap­proval for leukemia, kick­ing off show­down with Servi­er in IDH1

1 hour ago
FDA+
see latest stream
People

SQZ Biotech slash­es head­count by 60% as founder/CEO hits ex­it — while Syn­log­ic lays off 25%

Yesterday

Up­dat­ed: Catal­ent to cut about 600 jobs in In­di­ana, Mary­land and Texas

2 days ago

Sana, Codex­is lay off staff, reshuf­fle pipeline in bid to fo­cus cell ther­a­py, en­zyme en­gi­neer­ing work

2 days ago
Financing

Pfiz­er will in­vest $1.2B+ in Irish man­u­fac­tur­ing site, adding 500 em­ploy­ees

20 hours ago

In­tel­lia and Iver­ic sell stocks to raise mon­ey, each net­ting $300M

21 hours ago

CRO start­up Vial scores $67M Se­ries B led by Gen­er­al Cat­a­lyst

Yesterday
Startups

Lund­beck-part­nered pre­clin­i­cal biotech nabs Se­ries A from As­traZeneca

3 days ago

Ca­jal Neu­ro­science launch­es with $96M Se­ries A, tack­ling Alzheimer's and Parkin­son's

3 days ago

Lil­ly joins in ex­pand­ed Se­ries A round for BeiGene-part­nered mR­NA biotech

4 days ago
Deals

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

21 hours ago

Rally­bio, Ab­Cellera form new part­ner­ship around an­ti­bod­ies for rare dis­ease

Yesterday

BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

Yesterday

Premium storiesSee all

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

2 days ago
R&D
Pharma

Al­lo­gene takes the stage in New York to go deep on its off-the-shelf cell ther­a­pies — de­clar­ing a first for sol­id ...

2 days ago
Bioregnum
R&D

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

2 days ago
Pharma
Marketing

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

3 days ago
Deals
Cell/Gene Tx

In FocusSee all

Covid-19 spurred a his­toric vac­cine R&D ef­fort. What does it mean for fu­ture pan­demics?

Last month
R&D
Coronavirus

A biotech paused a gene ther­a­py hatched by fam­i­lies. Now they want con­trol

Last month
Cell/Gene Tx

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Last month
People
Pharma

Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

2 months ago
R&D
Pharma

Don't missSee all

Sy­neos Health pre­dicts phar­ma trends leap­ing for­ward in 2023 af­ter re­boot year

19 hours ago
Pharma
Marketing

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

20 hours ago
Pharma

As com­peti­tors near FDA goal­post, Roche spells out its re­peat Alzheimer's set­back

22 hours ago
R&D
Pharma

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Yesterday
R&D

Endpoints Standouts

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

6 months ago
People
Discovery

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

7 months ago
Special

The 2022 top 100 bio­phar­ma in­vestors: A look back on boom times

9 months ago
Financing
Deals

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

12 months ago
People
Special

Peer review See all

Nov
23

Ox­ford Bio­med­ica's next CEO to start in March; Kåre Schultz ready to wrap up Te­va tenure ear­ly

Nov
18

Ex-Ru­bius CEO dusts him­self off at a dif­fer­ent Flag­ship biotech; Hutchmed switch­es things up dur­ing pipeline re­fo­cus

Nov
11

Fourth time's the charm? blue­bird picks up new fi­nance chief; New CEOs here and there

Nov
4

Af­ter a one-year gap, Sage fi­nal­ly finds new CMO; Gut­ted by lay­offs, Flag­ship's Ru­bius reshuf­fles a not-so-full deck

Oct
28

Two Au­rinia ex­ecs are out — and CRISPR’s op­er­a­tions chief is­n't far be­hind; Bio­gen MS leader jumps to Eli Lil­ly ...

Pharma channel feed

2 days ago

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

Af­ter 24 years with­out con­firm­ing clin­i­cal ben­e­fit, the FDA an­nounced Tues­day morn­ing that Vi­a­tris (formed via My­lan and Pfiz­er's Up­john) has de­cid­ed to with­draw a top­i­cal an­timi­cro­bial ...

READ MORE

Ar­genx pur­chas­es $100M+ FDA pri­or­i­ty re­view vouch­er from blue­bird bio

Yesterday
FDA+

Nestlé re­con­sid­ers peanut al­ler­gy pro­gram two years af­ter $2.6B buy­out

2 days ago
latest in Pharma

Fed­er­al claims court rules in fa­vor of Gilead in CDC Tru­va­da patent case

18 hours ago
Law

As the amox­i­cillin short­age drags on, sev­er­al sen­a­tors pres­sure FDA and HHS for so­lu­tions

20 hours ago
Manufacturing

ICER rates Astel­las' po­ten­tial menopausal symp­tom drug as promis­ing at about $2K per year

21 hours ago

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

Yesterday
Cell/Gene Tx
Manufacturing

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

Yesterday
Manufacturing
see latest stories

Marketing channel feed

2 days ago

Mar­ket­ingRx roundup: Pfiz­er, BioN­Tech re-up iHeartRa­dio hol­i­day spon­sor­ship; WHO re­names mon­key­pox to 'm­pox'

It’s that time of year again for pop mu­sic fans with the re­turn of the iHeartRa­dio Jin­gle Ball tour — and Pfiz­er and BioN­Tech’s spon­sor­ship. For the sec­ond year, the Covid-19 vac­cine ...

READ MORE

Mer­ck­'s lat­est 'Why Vac­ci­nes' cam­paign seeks to bet­ter in­form vac­cine-hes­i­tant moms

3 days ago
Pharma

GSK physi­cian sur­vey finds lu­pus pa­tients at in­creased risk for or­gan dam­age

2 days ago
Pharma
latest in Marketing

Roivant’s Der­ma­vant de­buts first-ever TV com­mer­cial for pso­ri­a­sis cream Vta­ma

Last week
Pharma

Phar­ma re­new­able en­er­gy co-op sparks broad­er sup­pli­er push, fol­lows Wal­mart's lead

Last week
Pharma

Gam­ing for phar­ma: Re­al Chem­istry adds video game mar­ket­ing to agency ex­per­tise

Last week
Pharma

Phar­ma rep­u­ta­tion falls again, notch­ing dou­ble-dig­it down­turn over past year in US — sur­vey

Last week
Pharma

Mar­ket­ingRx roundup: Am­gen and Sto­ryCorps launch health eq­ui­ty se­ries; Ab­b­Vie's $40M math and sci­ence school opens

Last week
Pharma
see latest stories

FDA+ channel feed

4 days ago

Spec­trum im­plodes af­ter a harsh pub­lic slap­down and now a CRL from Richard Paz­dur

The FDA has gone out of its way sev­er­al times to flat­ten any ex­pec­ta­tions for Spec­trum’s lung can­cer drug pozi­o­tinib, in­clud­ing slam­ming the reg­u­la­to­ry door in the biotech's face four ...

READ MORE

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Yesterday

Up­dat­ed: Roche pulls PD-L1 block­buster's ac­cel­er­at­ed ap­proval in blad­der can­cer

3 days ago
Pharma
latest in FDA+

FDA ap­proves Re­by­ota, Fer­ring's poop-based drug to fight C. diff in­fec­tion

Yesterday

FDA re­jects Cri­net­ic­s' cur­rent PhII de­sign for hy­per­in­sulin­ism drug

2 days ago

In­dus­try groups, CVS pick apart FDA's pro­posed path­way for gener­ics to carve out OTC in­di­ca­tions

3 days ago

Fourth ac­cel­er­at­ed ap­proval in Duchenne? Sarep­ta gets pri­or­i­ty re­view for gene ther­a­py amid FDA scruti­ny

3 days ago
R&D

Sus­pend­ed Cal­i­for­nia cell ther­a­py man­u­fac­tur­ing site hit with FDA warn­ing let­ter over ma­jor qual­i­ty con­cerns

Last week
Pharma
Manufacturing
see latest stories

Manufacturing channel feed

3 days ago

FDA tells Catal­ent to fix is­sues at two man­u­fac­tur­ing sites on its own

The CD­MO Catal­ent will have to fix is­sues at two man­u­fac­tur­ing plants in the US and Eu­rope that were sub­ject to in­spec­tions by the FDA this sum­mer, giv­ing the com­pa­ny room to cor­rect the ...

READ MORE

Man­u­fac­tur­ing roundup: Touch­light nets $2M grant from the Gates Foun­da­tion; Ex­per­ic clos­es $14M Se­ries B

20 hours ago

Fo­s­un Phar­ma con­sid­ers $3.8B sale of In­di­an drug­mak­er Gland Phar­ma — re­port

2 days ago
Deals
Pharma
latest in Manufacturing

Re­silience pur­chas­es Ohio bio­man­u­fac­tur­ing site from As­traZeneca

2 days ago
Deals
Pharma

Sta­da to place $50M+ in­vest­ment in a new fa­cil­i­ty in Ro­ma­nia

3 days ago
Pharma

Post-Brex­it UK trade re­port shows 'wor­ry­ing' signs for life sci­ences

3 days ago
Pharma

No­vo Nordisk to spend $747M+ on ex­pan­sions and new fa­cil­i­ty in Den­mark

Last week
Pharma

Fu­ji­film to build $188M man­u­fac­tur­ing plant in North Car­oli­na’s re­search tri­an­gle

Last week
Pharma
see latest stories